20-F: Aesthetic Medical International Holdings Group Reports FY2025 Results

Aesthetic Medical International Holdings Group Limited announced its financial results for the fiscal year ended December 31, 2025, reporting a decrease in revenue and an increase in net loss.

Summary

• Aesthetic Medical International Holdings Group Limited reported a total revenue of RMB722.9 million (US$102.4 million) for the fiscal year ended December 31, 2025, a decrease of 4.3% from RMB755.7 million in 2024.
• The company experienced a net loss of RMB54.1 million (US$7.7 million) in 2025, an increase from a net loss of RMB25.1 million in 2024.
• Revenue from non-surgical aesthetic medical services decreased by 3.0% to RMB541.1 million, primarily due to a decline in energy-based treatments.
• Surgical aesthetic medical services revenue increased by 1.1% to RMB126.8 million, attributed to a strategic shift towards higher-margin services.
• General healthcare services and other aesthetic medical services revenue decreased by 24.1% to RMB55.0 million.
• Gross margin improved to 46.2% in 2025 from 44.7% in 2024, driven by the higher margin surgical services.
• Selling expenses decreased by 6.1% to RMB226.4 million, while general and administrative expenses increased slightly by 1.9% to RMB102.7 million.
• The company had net current liabilities of RMB294.1 million as of December 31, 2025, and is seeking additional financing to support its operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the revenue decline, increased net loss, and significant going concern issues raised by the auditor.

Positives

• Gross margin improved to 46.2% in 2025 from 44.7% in 2024, primarily due to a strategic focus on higher-margin surgical aesthetic medical services.
• Revenue from surgical aesthetic medical services increased by 1.1% to RMB126.8 million, indicating a positive shift in service mix.
• Selling expenses decreased by 6.1% to RMB226.4 million, reflecting cost control measures.
• The company has a strong brand reputation and has received several industry awards in 2023 and 2024, reinforcing its market position.

Negatives

• Total revenue decreased by 4.3% to RMB722.9 million in 2025 compared to 2024.
• The company reported a net loss of RMB54.1 million in 2025, an increase from RMB25.1 million in 2024.
• Non-surgical aesthetic medical services revenue declined by 3.0% to RMB541.1 million.
• General healthcare services and other aesthetic medical services revenue decreased by 24.1% to RMB55.0 million.
• The company has net current liabilities of RMB294.1 million as of December 31, 2025, raising concerns about its short-term financial health.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.

Risks

• The company's corporate structure, relying on contractual arrangements with certain PRC subsidiaries, carries unique risks to investors, including potential invalidation by PRC authorities.
• The company faces significant regulatory risks in China, including potential government intervention, changes in laws and regulations, and increased oversight over overseas listings.
• The company is subject to intense competition in the aesthetic medical services market, which could impact its market share and profitability.
• The company's business is sensitive to economic conditions, and a downturn could reduce customer spending on aesthetic services.
• The company may not be able to adequately protect its intellectual property rights, which could harm its brand and business.
• The company is subject to risks related to cybersecurity and data privacy, with potential liabilities arising from breaches or non-compliance with PRC regulations.
• The company's ADSs were delisted from Nasdaq and are now quoted on the OTCQX Best Market, which may result in reduced liquidity and increased price volatility.
• The company's ability to continue as a going concern is subject to uncertainty, as indicated by its auditor, due to its net loss and net current liabilities.

Future Outlook

The company's future outlook is uncertain due to a decrease in revenue, an increase in net loss, and substantial doubt raised by its auditor regarding its ability to continue as a going concern. The company plans to rely on additional financing and operational improvements to address these challenges.

Management Comments

• The total revenue from aesthetic medical services for 2025 decreased by 2.2% primarily due to the decrease in our energy-based treatments segment.
• The total revenue from surgical aesthetic medical services for 2025 increased by 1.1% primarily attributable to our strategic realignment of business priorities toward surgical aesthetic medical services, which offer higher gross profit margins.
• The total revenue from general healthcare services and other aesthetic medical services for 2025 decreased by 24.1% primarily driven by Shenzhen Pengchengs decrease in other aesthetic medical services.
• The gross margin for surgical aesthetic medical services increased to 58.0% from 54.7% in 2024.
• The gross margin for general healthcare services and other aesthetic medical services increased to 47.7% from 36.5% in 2024.
• The company's ability to continue as a going concern is primarily dependent on the Groups ability to arrange adequate financing arrangements and generate cash flows from its operations.

Industry Context

StockSavvy.ai notes that the aesthetic medical market in China is projected for significant growth, with non-surgical treatments expected to lead. However, Aesthetic Medical International Holdings Group's performance in 2025 indicates challenges in navigating market conditions and regulatory environments, despite the overall industry growth potential.

Comparison to Industry Standards

• The company's revenue decline in 2025 contrasts with the projected growth of the Chinese non-surgical aesthetic medical market, which is expected to reach RMB415.7 billion by 2030.
• The company's net loss and net current liabilities raise concerns about its financial stability compared to industry peers who may be better positioned to capitalize on market growth.
• The improvement in gross margin for surgical services is a positive sign, aligning with industry trends where higher-margin procedures can bolster profitability.

Legal Proceedings

• The company was named as the defendant in 21 ongoing litigations for its consolidated businesses in the PRC, with aggregate claimed damages amounting to RMB45.0 million.

Related Party Transactions

• The company entered into a lease agreement with Shenzhen Jiayan Investment Industrial Development Co., Ltd., which is wholly owned by directors Dr. Zhou Pengwu and Ms. Ding Wenting.
• The company has provided personal guarantees from directors and corporate guarantees from related companies for its borrowings.
• The company has outstanding balances due from related parties, including amounts due from related companies and non-controlling interests.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity financing.
• Investors face risks related to the company's corporate structure, potential delisting, and the uncertainties of operating in the PRC.
• The company's financial condition and results of operations could be adversely affected by changes in PRC economic, political, and social conditions, as well as governmental policies.

Next Steps

• The company plans to continue focusing on its core markets in the Guangdong-Hong Kong-Macau Greater Bay Area and the Yangtze Delta Area.
• The company intends to reinvest earnings to operate and expand its business and does not expect to declare dividends in the foreseeable future.
• The company will continue to monitor interest rate risk exposure and consider hedging significant interest rate risk exposure should the need arise.
• The company will continue to make capital expenditures to meet the expected growth of its business.

Key Dates

Recommendation

The company's deteriorating financial performance, including revenue decline and increased net loss, coupled with substantial doubt about its going concern status raised by the auditor, warrants a sell recommendation. The company's reliance on contractual arrangements in China and its delisting from Nasdaq further add to the significant risks for investors.

Keywords

Aesthetic Medical International Holdings Group, Form 20-F, SEC Filing, Annual Report, Financial Results, Revenue, Net Loss, China, Medical Aesthetics, PRC Regulations, Contractual Arrangements, Going Concern